---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-004004"
form_type: "8-K"
ticker: "OCEA"
cik: "0001869974"
company_name: "Ocean Biomedical, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T21:02:21.459288+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ocean Biomedical awarded multiple patents for CHI3L1 antibody cancer therapies; deal with Aesther SPAC pending

## Summary
- Dr. Jack A. Elias granted patents for mono-specific and bispecific antibodies targeting CHI3L1 to suppress multiple cancers.
- Antibodies cover CHI3L1 alone, CHI3L1/PD-1 bispecific, and CHI3L1/CTLA4 bispecific.
- Technology described as 'master regulator' of immune checkpoint pathways; shown to control lung cancer in murine models.
- Ocean Biomedical expected to list on Nasdaq under OCEA/OCEAW after business combination with Aesther (AEHA).
- Patents cover prostate, colon, ovarian, breast, lung cancers, glioblastoma, melanoma, etc.

## SEC filing metadata
- accession: 0001493152-23-004004
- form_type: 8-K
- ticker: OCEA
- cik: 0001869974
- company_name: Ocean Biomedical, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869974/000149315223004004/0001493152-23-004004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869974/000149315223004004/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-004004
- JSON: https://secwatch.observer/filing/0001493152-23-004004.json
- Plain text: https://secwatch.observer/filing/0001493152-23-004004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.